Invivyd (IVVD) announced that PEMGARDA, its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network, NCCN, Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America, IDSA, that updated its COVID-19 guidelines in August 2024 to recommend the use of PEMGARDA for pre-exposure prophylaxis, PrEP, in moderately to severely immunocompromised adults and adolescents at risk for progression to severe COVID-19 when predominant regional variants are susceptible to pemivibart. This inclusion in the NCCN Guidelines recognizes PEMGARDA as a potential option for PrEP against COVID-19 in patients with B-cell malignancies. Immunocompromised patients may not mount an adequate immune response to vaccination.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd ‘commends’ FDA focus on uncertainty around COVID-19 vaccine boosters
- Invivyd Holds Annual Stockholders Meeting, Elects Directors
- Invivyd Reports Q1 2025 Financial Results and Outlook
- Invivyd’s Earnings Call: Strategic Moves Amid Challenges
- Invivyd Reports Q1 2025 Financial Results and Highlights